Pipeline Advancements Will Unlock Global Therapeutic Potential
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
29 Apr 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$14.00
88.5% undervalued intrinsic discount08 Aug
US$1.61
1Y
73.1%7D
8.8%